
Mark Denison
Director, Pediatric Infectious Diseases · Vanderbilt University Medical Center
Credentials: · ·
History
- 2023–2026
Pediatric Infectious Diseases
- 2022–2025
Pediatrics
Research
An mRNA Vaccine against SARS-CoV-2 - Preliminary Report
New England Journal of Medicine · 2020 · 2,556 citations
SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness
Nature · 2020 · 1,324 citations
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
New England Journal of Medicine · 2020 · 1,249 citations

22 papers
- JM
8 papers

8 papers

6 papers

4 papers
- EA
4 papers

4 papers

4 papers
Grants
- 2011–2026
Childhood Infections Research Program
National Institute of Allergy and Infectious Diseases · T32
Contact PI · $3.3M · Vanderbilt University Medical Center
- 2013–2025
Determinants of Coronavirus Fidelity in Replication and Pathogenesis
National Institute of Allergy and Infectious Diseases · R01
Contact PI · $6.5M · Vanderbilt University Medical Center
- 2019–2025
Antiviral Drug Discovery and Development Center (AD3C)
National Institute of Allergy and Infectious Diseases · U19
Project lead · $5.2M · University of Alabama at Birmingham
- 2014–2020
Antiviral Drug Discovery and Development Center - Overall
National Institute of Allergy and Infectious Diseases · U19
Project lead · $4.7M · University of Alabama at Birmingham
